Company intelligence / Profile preview

Gameto

New York, New York, United Statesgametogen.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Gameto’s lead program, Fertilo, uses engineered ovarian support cells to mature eggs outside the body, aiming to make IVF and egg freezing shorter, safer, and more accessible. The technology has received FDA clearance to proceed toward Phase III trials in the US. Early clinical use has begun internationally. The company also develops programs targeting menopause using similar cellular engineering approaches[1][5].

Therapeutic areas: Women's Health
Modalities: Cell therapy (engineered ovarian support cells derived from human induced pluripotent stem cells)
Industry: Biotech

Drug pipeline

3 assets

Fertilo

2 more assets in the full pipeline.

Partnerships

ARPA-H Sprint for Women’s Health Initiative funding award[1]Sponsored research with Professor George Church's lab at Harvard Medical School[2]

Beyond the preview

Go deeper on Gameto.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gameto.